Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.5269
-0.0081-1.51%
Post-market: 0.53030.0034+0.65%16:50 EDT
Volume:1.97M
Turnover:1.05M
Market Cap:125.19M
PE:-1.40
High:0.5417
Open:0.5300
Low:0.5200
Close:0.5350
Loading ...

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday

Benzinga
·
18 Mar

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
18 Mar

Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
18 Mar

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

Benzinga
·
18 Mar

BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11 Vs. IBES Estimate USD -0.09

Reuters
·
18 Mar

Sangamo Therapeutics Q4 Operating Expenses USD 33.5 Million

THOMSON REUTERS
·
18 Mar

Sangamo options imply 29.8% move in share price post-earnings

TIPRANKS
·
18 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Sangamo Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
15 Mar

Sangamo Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
07 Mar

Press Release: Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Dow Jones
·
07 Mar

Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%

Simply Wall St.
·
28 Feb

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Benzinga
·
22 Feb

Sangamo Therapeutics Inc - Isaralgagene Civaparvovec Generally Well-Tolerated With Most Adverse Events Grade 1-2

THOMSON REUTERS
·
06 Feb

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

THOMSON REUTERS
·
06 Feb

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Jan

Sangamo Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
24 Jan

Truist Financial Keeps Their Buy Rating on Sangamo Biosciences (SGMO)

TIPRANKS
·
23 Jan

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025

Insider Monkey
·
08 Jan

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

Zacks
·
03 Jan